Login to Your Account

Hua raises $50M, preps for phase III GKA study in type 2 diabetes

By Shannon Ellis
Staff Writer

Monday, April 25, 2016

SHANGHAI – Hua Medicine Ltd. has raised $50 million in a series C investment led by China-based Harvest Investments. Hua is now preparing a phase III trial for its lead candidate, HMS5552.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription